TABLE 4.
Secondary outcomesa
| Outcome | RVP count | %RVP (95% CI) | RPP count | %RPP (95% CI) | P |
|---|---|---|---|---|---|
| Admission with a positive test | 140/158 | 88.6 (82.6–92.7) | 290/377 | 76.9 (72.4–80.9) | 0.013 |
| Admission with a negative test | 264/303 | 87.1 (82.9–90.5) | 568/666 | 85.3 (82.4–87.8) | 0.726 |
| Test performed in the ED | 49/110 | 44.6 (35.5–54.0) | 191/234 | 81.6 (76.1–86.1) | <0.001 |
| 30-day readmittance | 12/110 | 10.9 (6.3–18.3) | 35/234 | 15.0 (10.9–20.1) | 0.311 |
| In-hospital death | 4/110 | 3.6 (1.4–9.3) | 4/234 | 1.7 (0.6–4.5) | 0.281 |
| C. difficile infection | 0/110 | NAb | 3/234 | 1.3 (0.4,3.9) | NA |
| Allergic reactions | 0/110 | NA | 0/234 | NA | NA |
| Appropriate oseltamivirc | 23/26 | 88.5 (69.5–96.3) | 84/93 | 90.3 (82.3–95.0) | 0.781 |
a
Counts are expressed as the number of affected subjects/total number of subjects examined.
b
NA, not applicable.
c
Appropriate oseltamivir is defined as the use of oseltamivir in patients testing positive for influenza A or B.